Insomnia – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of insomnia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s insomnia forecast will answer the following questions:

• Of all people diagnosed with insomnia, how many in each country in the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of insomnia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts four insomnia patient populations, as follows:

• Total prevalent cases of insomnia based on DSM-5 criteria
• Total prevalent cases of insomnia based on DSM-IV criteria
• Total prevalent cases of insomnia (DSM-5) by comorbidity
• Total prevalent cases of insomnia (DSM-IV) by comorbidity

Note: Coverage may vary by country.